rheumatology
Medicines

Apremilast heals oral ulcers in Behçet’s

Apremilast reduces the number of oral ulcers in Behçet’s syndrome, results of a phase II trial show.  The randomized placebo-controlled trial involved 111 patients in Turkey and the United States who were treated for 12-24 weeks. The average number of oral ulcers at week 12 was significantly lower in the apremilast group (0.5) than in the ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic